Copanlisib: all 66 studies that test it

Page 1 of 1. Open to participants first (0), then studies with results posted, then the rest; newest registration first within each.

• Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Expression (MATCH - Subprotocol Z1H)Active, not recruitingNCT06400238Phase 2Results posted
• Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Loss (MATCH - Subprotocol Z1G)Active, not recruitingNCT06360588Phase 2Results posted
• Testing Copanlisib as a Potential Targeted Treatment in Cancers With PIK3CA Mutations (MATCH-Subprotocol Z1F)Active, not recruitingNCT05490771Phase 2Results posted
• Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN AlterationsTerminatedNCT05082025Phase 2Results posted
• Copanlisib With Dose-Adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and Other High-Grade B-cell LymphomasTerminatedNCT04933617Phase 1Results posted
• Study of Copanlisib and Ketogenic DietTerminatedNCT04750941Phase 2Results posted
• Vemurafenib Plus Copanlisib in Radioiodine-Refractory (RAIR) Thyroid CancersCompletedNCT04462471Phase 1Results posted
• Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast CancerActive, not recruitingNCT04345913Phase 1/2Results posted
• Bendamustine and Rituximab in Combination With Copanlisib for the Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaTerminatedNCT04155840Phase 2Results posted
• Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Maintenance Treatment (Trastuzumab and Pertuzumab) After Initial Chemotherapy in a Phase Ib/II Trial for Advanced HER2 Positive Breast CancerTerminatedNCT04108858Phase 1/2Results posted
• Testing the Addition of Copanlisib to Usual Treatment (Fulvestrant and Abemaciclib) in Metastatic Breast CancerActive, not recruitingNCT03939897Phase 1Results posted
• A Study of Copanlisib and Ibrutinib in Mantle Cell LymphomaCompletedNCT03877055Phase 1/2Results posted
• Testing the Combination of the Anti-cancer Drugs Copanlisib, Olaparib, and MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumors With Selected MutationsActive, not recruitingNCT03842228Phase 1Results posted
• Response-Adapted Therapy With Copanlisib and Rituximab in Untreated Follicular LymphomaActive, not recruitingNCT03789240Phase 2Results posted
• Study of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal CancerCompletedNCT03711058Phase 1/2Results posted
• Effect of Copanlisib on Metformin Pharmacokinetics and PharmacodynamicsCompletedNCT03655301Phase 1Results posted
• Copanlisib Hydrochloride and Nivolumab in Treating Patients With Recurrent or Refractory Diffuse Large B-cell Lymphoma or Primary Mediastinal Large B-cell LymphomaCompletedNCT03484819Phase 2Results posted
• Safety, Tolerability, Efficacy and Pharmacokinetics of Copanlisib in Pediatric PatientsTerminatedNCT03458728Phase 1/2Results posted
• Study of Copanlisib in Hepatic or Renal ImpairmentCompletedNCT03172884Phase 1Results posted
• Copanlisib in Treating Patients With Persistent or Recurrent Endometrial CancerCompletedNCT02728258Phase 2Results posted
• Copanlisib (BAY 80-6946) in Combination With Gemcitabine and Cisplatin in Advanced CholangiocarcinomaCompletedNCT02631590Phase 2Results posted
• Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)TerminatedNCT02626455Phase 3Results posted
• Phase II Copanlisib in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)CompletedNCT02391116Phase 2Results posted
• Phase III Copanlisib in Rituximab-refractory iNHLCompletedNCT02369016Phase 3Results posted
• Copanlisib and Rituximab in Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL)CompletedNCT02367040Phase 3Results posted
• Open-label, Uncontrolled Phase II Trial of Intravenous PI3K Inhibitor BAY80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's LymphomasCompletedNCT01660451Phase 2Results posted
• A Study of Copanlisib in Combination with Degarelix in People with Prostate CancerWithdrawnNCT06218667Phase 1/2
• Copanlisib and Avelumab as a Maintenance Therapy for Advanced Bladder CancerWithdrawnNCT05687721Phase 1/2
• A Prospective Multicenter Phase 2 Study of the Chemotherapy-Free Combination of the Intravenous Phosphatidylinositol-3-Kinase (PI3K) Inhibitor Copanlisib in Combination With Obinutuzumab in Patients With Previously Untreated Follicular Lymphoma (FL) and a High Tumor BurdenActive, not recruitingNCT05387616Phase 2
• Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor TherapyWithdrawnNCT05295589Phase 2
• BAY1895344 and Copanlisib for the Treatment of Molecularly Selected Patients With Advanced Solid TumorsWithdrawnNCT05010096Phase 1
• Copanlisib and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell LymphomaActive, not recruitingNCT04939272Phase 1/2
• Lung Cancer With Copanlisib and DurvalumabCompletedNCT04895579Phase 1
• Window Trial to Evaluate Molecular Response to PI3K Inhibition With Copanlisib in r/r Adult B-cell ALLTerminatedNCT04803123Early Phase 1
• Copanlisib Plus Ibrutinib or Acalabrutinib in R/R CLLWithdrawnNCT04685915Phase 2
• Copanlisib Plus Venetoclax in R/R DLBCLActive, not recruitingNCT04572763Phase 1/2
• Copanlisib With Rituximab-Bendamustine in Patients With Relapsed-Refractory Diffuse Large B-cell LymphomaTerminatedNCT04433182Phase 2
• Dose De-escalation Study of the PI3k Alpha/Delta Inhibitor, Copanlisib Given in Combination With the Immunotherapeutic Agents, Nivolumab and Rituximab in Patients With Relapsed/Refractory Indolent LymphomaTerminatedNCT04431635Phase 1
• Copanlisib in Combination With Rituximab and CHOP Chemotherapy in Patients With Previously Untreated DLBCLCompletedNCT04263584Phase 2
• A Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate CancerActive, not recruitingNCT04253262Phase 1/2
• Copanlisib in Combination With Romidepsin in Patients With Relapsed or Refractory Mature T-cell LymphomaWithdrawnNCT04233697Phase 1
• Copanlisib and Combination Chemotherapy for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Relapsed Grade 3b Follicular LymphomaTerminatedNCT04156828Phase 1
• Copanlisib in Combination With T-DM1 in Pretreated Unresectable Locally Advanced or Metastatic HER2-positive Breast CancerTerminatedNCT04042051Phase 1
• Copanlisib in Combination With Venetoclax in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma.TerminatedNCT03886649Phase 1
• Copanlisib and Nivolumab in Treating Patients With Richter's Transformation or Transformed Indolent Non-Hodgkin LymphomaActive, not recruitingNCT03884998Phase 1
• Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialTerminatedNCT03878524Phase 1
• A Study of a New Drug Combination, Copanlisib and Fulvestrant, in Advanced Breast CancerWithdrawnNCT03803761Phase 1/2
• An Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Advanced Solid TumorsCompletedNCT03735628Phase 1
• Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube CancerCompletedNCT03586661Phase 1
• Copanlisib With Ibrutinib for Patients With Recurrent/ Refractory Primary Central Nervous System Lymphoma (PCNSL)CompletedNCT03581942Phase 1/2
• Phase 1 Study of the Combination of Rogaratinib With Copanlisib in Patients With Fibroblast Growth Factor Receptor (FGFR)-Positive, Locally Advanced or Metastatic Solid TumorsCompletedNCT03517956Phase 1
• Copanlisib Chinese PK StudyCompletedNCT03498430Phase 1
• Copanlisib and Rituximab in Marginal Zone Lymphoma PatientsActive, not recruitingNCT03474744Phase 2
• Fulvestrant and Palbociclib With or Without Copanlisib in Treating Patients With Hormone Receptor Positive, HER2 Negative, Stage IV Breast CancerWithdrawnNCT03377101Phase 2
• Copanlisib and Gemcitabine in Relapsed/Refractory PTCLCompletedNCT03052933Phase 1/2
• Copanlisib in Association With Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinomas Harboring a PI3KCA Mutation/Amplification and/or a PTEN LossTerminatedNCT02822482Phase 1/2
• Phase Ib/II Trial of coPANlisib in Combination With Trastuzumab in HER2-positive Breast Cancer. (Panther Study)CompletedNCT02705859Phase 1
• Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)Active, not recruitingNCT02465060Phase 2
• Phase IIa Study of Copanlisib in Relapsed or Refractory Mantle Cell Lymphoma (MCL)TerminatedNCT02455297Phase 2
• Japanese Phase Ib/II Copanlisib in Relapsed, Indolent B-cell NHLCompletedNCT02342665Phase 1/2
• COPANLISIB (BAY80-6946) Drug-drug Interaction and Cardiovascular Safety Study in Advanced Solid Tumor and Non-Hodgkin's Lymphoma PatientsCompletedNCT02253420Phase 1
• Copanlisib Pharmacodynamic StudyCompletedNCT02155582Phase 1
• Copanlisib Mass Balance StudyCompletedNCT02119221Phase 1
• Phase I Study of PI3(Phosphoinositol 3)-Kinase Inhibitor BAY80-6946 With Paclitaxel in Patients With Advanced CancerCompletedNCT01411410Phase 1
• Japanese BAY80-6946 Monotherapy Phase I StudyCompletedNCT01404390Phase 1
• BAY80-6946 Open Label, Phase I Study in Patients With Advanced CancerCompletedNCT00962611Phase 1

← Copanlisib overview